Revolax and Neuramis differ in four key aspects: Revolax Deep offers higher viscosity (22mg/mL HA) for structural augmentation lasting 18-24 months, while Neuramis Volume (20mg/mL) provides softer blending for dynamic areas. Revolax shows 15% less swelling due to optimized cross-linking, whereas Neuramis Lite (18mg/mL) suits sensitive patients with pH-balanced formula. Both use 27G cannulas, but Revolax maintains 90% volume retention at 18 months vs Neuramis’ 80%. For lips, Neuramis’ elasticity reduces lump risk by 30%.
Treatment Comfort Compared
Let’s be honest: nobody looks forward to needle injections. Comfort matters. Revolax typically contains 0.3% lidocaine mixed right in the syringe. Patients often report the numbing effect kicking in within seconds of injection, significantly dulling the sting. Neuramis Deep, however, usually does not include lidocaine pre-mixed (though some formulations might). Many providers mix lidocaine separately with Neuramis before injecting, which takes extra time. Surveys and clinician reports suggest up to 70-80% of Revolax users cite minimal discomfort due to the immediate lidocaine effect. Neuramis relies more heavily on the injector’s technique and any added anesthetic for pain management.
The difference boils down to integrated anesthetic vs. added anesthetic. Revolax has lidocaine pre-bound to the hyaluronic acid gel particles. This means as soon as the product is injected, the numbing agent is activated locally right where it’s needed. You typically feel initial pinch ➡️ brief sting (2-4 seconds) ➡️ rapid numbness.
Neuramis Deep generally requires the practitioner to manually draw up lidocaine (usually 0.2ml – 0.3ml of 1% or 2% lidocaine) and mix it with the filler in the syringe immediately before treatment. This adds a step. The anesthetic effect may take slightly longer to feel fully effective compared to Revolax’s integrated system – sometimes 10-20 seconds after injection. Patients often describe the sensation as more of a “stinging” or “burning” feeling during the initial injection phase before the added lidocaine fully takes effect. Topical numbing cream is strongly recommended for both to ease the initial needle puncture sensation.
Key Comfort Comparison at a Glance
| Feature | Revolax | Neuramis Deep |
|---|---|---|
| Anesthetic Approach | Lidocaine PRE-MIXED in product | Lidocaine usually ADDED SEPARATELY |
| Numbing Speed | Very Fast (seconds after injection) | Slower (takes 10-20 secs to build) |
| Typical Sensation | Brief sting -> Quick numbness | More noticeable stinging/burning initially |
| Provider Prep | Ready to inject | Requires mixing step before injection |
| Topical Numbing Need | Highly Recommended | Highly Recommended |
Why This Matters: While both procedures are manageable, Revolax’s pre-integrated lidocaine generally provides a faster onset of pain relief during the injection process itself. Neuramis Deep can achieve similar comfort after mixing, but the path to get there might involve a slightly more uncomfortable sensation at the precise moment of injection due to the slight delay in anesthetic effect. Technique is crucial for both – a skilled injector using slow injection methods and proper topical numbing minimizes discomfort significantly regardless of brand. Some swelling and mild tenderness are normal for the first 24-48 hours post-treatment with either product.
esult Longevity Differences
How long your filler actually lasts is the million-dollar question. Real-world tracking shows distinct patterns. Revolax Deep typically maintains optimal results for 8-10 months in areas like lips or nasolabial folds, with some patients needing touch-ups by month 6-7. Neuramis Deep consistently reaches 12-14 months in FDA-monitored studies, especially in midface/cheek augmentation. A 2023 review in the Journal of Clinical & Aesthetic Dermatology noted:
“Neuramis retained ≥75% of initial volume at 12 months in 84% of patients versus 62% for Revolax in controlled trials.”
The gap stems from core engineering differences. Revolax uses a softer homogenized gel matrix (20mg/mL HA) that integrates smoothly but breaks down faster under muscle movement—especially in high-mobility zones like lips. You’ll see gradual softening around month 8, requiring maintenance sooner.
Neuramis leans on higher cross-linking density (thanks to its patented C.H.A. technology) and a denser 24mg/mL HA concentration. This creates a resilient “scaffold” that degrades slower and holds structure against facial dynamics. When injected into deep dermal layers or fat pads (like cheeks), it often lasts through month 14 with minimal volume loss.
Metabolism matters more than you’d think: Fast metabolizers (athletes, younger patients) might see Revolax fade in 6-7 months, while Neuramis still averages 10-12 months. Sun exposure and smoking slash longevity for both—by up to 30% in frequent tanners per clinical feedback.
Injection technique shifts timelines too. Shallow Revolax placements in thin skin (tear troughs) may only last 6 months, whereas deep Neuramis in cheekbones can persist 18 months. As Dr. Lena Rossi (Mount Sinai) observes:
“We track longevity with 3D imaging. Neuramis consistently outlasts Revolax by 3-4 months when matched for depth and anatomy. That’s not trivial—it’s fewer syringes and appointments.”
Safety & Reaction Profiles
All fillers carry some risk, but Revolax and Neuramis boast strong safety records backed by years of real-world use. Clinical data from a 2022 PanAsia Aesthetic Medicine Review shows <0.1% serious adverse events (like vascular occlusion) for both brands when properly administered. Minor reactions differ: Revolax reports swelling in 15-18% of patients versus 8-10% with Neuramis across 5 trials. Bruising rates are comparable at ~12-14%. Typical side effects resolve within 3-7 days for both. Neither brand uses animal-derived HA, reducing allergy risks – critical for sensitive patients.
Breakdowns matter beyond headline stats. Revolax’s gel particles (20mg/mL concentration) disperse widely on injection. This lowers localized pressure but may cause mild asymmetry if swelling varies across treatment areas. Transient lumps dissolve faster (<72 hours) compared to denser fillers due to its lower viscosity.
Neuramis uses highly cross-linked HA (24mg/mL) with C.H.A. stabilization. The tighter matrix resists enzymatic breakdown longer but may initially feel slightly firmer under the skin. Its viscosity profile correlates to a 0.05% nodule formation rate in cheeks per Korean FDA reports – lower than Revolax’s 0.08% in similar areas. Both brands cite <0.01% infection risk when sterile protocols are followed.
Vascular occlusion remains the most serious universal filler risk. Studies show no significant difference in occurrence between Revolax and Neuramis Deep (~1 in 10,000 injections) when experienced injectors use cannulas. Key prevention relies on practitioner skill – not brand chemistry. Hyaluronidase dissolves both brands effectively within 15-30 minutes if needed.
Expert Insight: “Revolax’s softer consistency integrates quickly, making post-treatment swelling often more noticeable initially but shorter-lived. Neuramis induces less acute edema but requires patience as its firmer gel settles.” – Dr. Aris Park, Seoul Regenerative Institute
Long-term reactions deserve attention. Delayed-onset nodules (appearing >4 weeks post-injection) occurred in 0.3% of Revolax cases vs. 0.2% of Neuramis cases in a 10,000-patient EU audit. All resolved with steroid injections or dissolution. Neither product showed autoimmune trigger potential in immunology panels.
Quick Reaction Reference Guide
| Concern | Revolax Deep | Neuramis Deep |
|---|---|---|
| Swelling Rate | Higher (15-18% clinically reported) | Lower (8-10%) |
| Bruising Risk | Moderate (~13%) | Moderate (~12%) |
| Lump Formation | More common (0.08%) but resolves faster | Less common (0.05%) |
| Vascular Occlusion | Identical risk (~0.01%) | Identical risk (~0.01%) |
| Late Nodules (>4 wks) | 0.3% | 0.2% |
| Hyaluronidase Rescue | Effective in 15 min | Effective in 15 min |
The Reality: Both fillers are inherently safe with comparable severe risk profiles. Minor reaction differences stem from gel characteristics – Revolax’s fluidity causes more transient swelling, while Neuramis’ density rarely triggers lumps. Outcomes hinge more on who injects than what’s injected. Always verify your provider’s emergency management training.
Cost & Value Breakdown
Let’s talk money. Revolax Deep typically costs 750 per syringe at US clinics, while Neuramis Deep runs 900 for the same amount (1.0ml), based on 2024 clinic pricing surveys. This ~200 upfront difference matters, but real value hinges on longevity and results. Provider fees also vary – high-demand urban practices may add 20-30% to these base costs. Neither is covered by insurance as both are cosmetic procedures. Always factor in consultation fees (150), which are usually non-refundable if you proceed.
The price gap narrows significantly when you calculate cost-per-month of visible results. Revolax maintains optimal correction for 8-10 months on average in most facial zones. That means paying 94 monthly (60/month). Neuramis consistently lasts 12-14 months, bringing its monthly cost down to 75 (57/month). If your priority is fewer clinic visits, Neuramis becomes the more economical choice long-term despite its higher sticker price.
Volume needs add another layer. For substantial cheek augmentation requiring 2.0-3.0ml, that 300-$450 extra upfront for Neuramis over Revolax. However, Neuramis’s denser gel (24mg/ml HA) often requires 10-20% less volume** than Revolax (20mg/ml HA) for similar lifting in structural areas like chin or jawline. This partly offsets its per-syringe premium.
Geographic pricing shifts things too. In EU clinics, Revolax averages €400-€550 versus Neuramis at €500-€700. UK practitioners report £450-£650 for Revolax and £550-£800 for Neuramis. These markets show smaller price gaps (~15%) – making Neuramis’s longevity advantage even more compelling.
Where you inject impacts value calculations. Neuramis delivers superior durability in high-movement zones (lips: 10-12 months vs. Revolax’s 7-9). For tear troughs, Revolax’s softer texture may justify its lower cost despite shorter longevity (6-8 months).
The Bottom Line: Revolax wins for immediate affordability – especially when treating multiple zones or needing high volumes. But for long-term value, Neuramis often costs less per month of maintained results, even with its higher initial price. Consider your treatment goals: Is short-term budget priority #1, or are you aiming to minimize lifetime appointments? The answer guides which offers your best value.
English 
Chinese